Evidence map›Paper›PMID 41071063›Full record

ArticleRheumatology (Oxford, England)2026

Tubulointerstitial inflammation driving interstitial fibrosis and tubular atrophy predicts poor renal outcome in refractory lupus nephritis.

Yevgeniya Gartshteyn, Shuwei Wang, Laura Geraldino-Pardilla, Adam Mor, Vivette D D'Agati, Robert Winchester

Abstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Apoptotic Bodies in Kidney Disease: Orchestrators of Inflammation, Fibrosis, and Repair.Journal of the American Society of Nephrology : JASN · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yevgeniya GartshteynDivision of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0001-5547-4658
Shuwei WangDivision of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Laura Geraldino-PardillaDivision of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Adam MorDivision of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.
Vivette D D'AgatiDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.
Robert WinchesterDivision of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.

Funding

Novel mechanisms regulating PD-1 signaling and functionR01AI125640 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Adam Mor · 2016 to 2026
$4.3M
A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse eventsR01AI175498 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Adam Mor, Robert J Winchester · 2023 to 2026
$2.9M
PAG is a novel target in immunotherapyR01AI150597 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOR, ADAM · 2020 to 2024
$2.7M
National Institute of Health R01AI150597NIAID NIH HHS R01 AI125640NIAID NIH HHS R01 AI150597NIAID NIH HHS R01 AI175498
6 · The paper itself

Abstract

objectiveInterstitial fibrosis and tubular atrophy (IF/TA) predicts end-stage kidney disease (ESKD) in lupus nephritis (LN). Repeat kidney biopsies were evaluated to identify variables driving progression of IF/TA and ESKD.

methodsLN patients with ≥2 biopsies from 1994 to 2018 were identified. Biopsies were interpreted by nephropathologists and classified according to ISN/RPS criteria. Clinical outcomes were ascertained through 2023. Multiplex immunohistochemistry was used to characterize the tubulointerstitial inflammation (TII).

resultsOne hundred and four LN patients [84% female, age 25 (+/-12) years at diagnosis, 14% White, 40% Black, 35% Hispanic] with a median follow-up of 11 (6-16) years were identified. On initial biopsy, 90% had class III or IV proliferative LN with or without class V. Forty-seven patients developed ESKD. We identified proteinuria, the presence of cellular and fibrocellular crescents, and IF/TA ≥ 25% at the first biopsy to be associated with the composite outcome of ESKD, chronic kidney disease (CKD) or death. In the absence of chronicity, persistent TII ≥ 25% was the only histological predictor of ESKD (OR 4.13; 95% CI: 1.06, 16.06). The severity of TII on one biopsy predicted the extent of IF/TA on the subsequent biopsy. The increase in TII between the first and second biopsies was particularly high in the subgroup of patients that progressed rapidly to advanced IF/TA and ESKD. Multiplex immunohistochemistry revealed that TII could occur as tubulitis mediated by CD8 T cells or as organized T and B cell rich infiltrates reminiscent of tertiary lymphoid structures.

conclusionTII predicts the development of IF/TA in LN and independently from glomerulosclerosis is associated with progression to ESKD.

Indexed as

Kidney Failure, ChronicKidney TubulesLupus NephritisNephritis, InterstitialAdultAtrophyBiopsyDisease ProgressionFemaleFibrosisHumansKidneyMaleMiddle AgedPrognosisRetrospective Studiesglomerulonephritislupuslupus nephritistubulointerstitial inflammation

Identifiers

PMID41071063
PMCPMC13233334

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.